Coherus Oncology (CHRS) FCF Margin (2013 - 2026)

Coherus Oncology has disclosed FCF Margin across 13 years of filings, most recently posting 470.24% for Q1 2026.

• FCF Margin for Q1 2026 came in at 470.24%, down 6827.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 649.38% (up 53644.0% YoY), and the FY2025 annual result was 786.76%, up 89.0% from the prior year.
• FCF Margin came in at 470.24% for Q1 2026 at Coherus Oncology, down from 220.36% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 6111.66% in Q1 2024 to a low of 1024.72% in Q3 2024.
• The 5-year median for FCF Margin is 84.65% (2022), against an average of 491.02%.
• Across the five-year window, FCF Margin soared 632402 bps in 2024 and slumped 651362 bps in 2025, its largest moves.
• Coherus Oncology's FCF Margin stood at 220.59% in 2022, then soared by 94 bps to 14.17% in 2023, then soared by 2710 bps to 369.95% in 2024, then slumped by 160 bps to 220.36% in 2025, then plunged by 113 bps to 470.24% in 2026.
• The last three FCF Margin figures came in at 470.24% (Q1 2026), 220.36% (Q4 2025), and 400.48% (Q3 2025), per Business Quant data.